Azficel-T
| Clinical data | |
|---|---|
| Trade names | Laviv |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| License data | |
| Routes of administration | Intradermal |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| DrugBank | |
| UNII | |
Azficel-T, sold under the brand name Laviv, is a cell therapy product for the improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults.[1][2][3] It consists of fibroblasts harvested from the patient's own skin.[2]
It was approved for medical use in the United States in June 2011.[2]
References
- 1 2 "Laviv (Azficel-T)". U.S. Food and Drug Administration (FDA). 22 July 2017. Retrieved 1 April 2020.
- 1 2 3 4 "Autologous Fibroblasts". U.S. Food and Drug Administration (FDA). 29 June 2017. Archived from the original on 22 July 2017. Retrieved 1 April 2020.
{{cite web}}: CS1 maint: unfit URL (link) - ↑ "Laviv (azficel-T) Suspension for Intradermal Injection" (PDF). Retrieved 2 April 2020.
Further reading
- Smith SR, Munavalli G, Weiss R, et al. (July 2012). "A multicenter, double-blind, placebo-controlled trial of autologous fibroblast therapy for the treatment of nasolabial fold wrinkles". Dermatol Surg. 38 (7 Pt 2): 1234–43. doi:10.1111/j.1524-4725.2012.02349.x. PMID 22409385. S2CID 24901992.
External links
- "Azficel-T". Drug Information Portal. U.S. National Library of Medicine.
- "Laviv (azficel-T)". Medscape. 28 September 2019.
- Clinical trial number NCT02120781 for "Controlled Study to Evaluate the Safety and Efficacy of Azficel-T for the Treatment of Vocal Fold Scarring and Age-Related Dysphonia" at ClinicalTrials.gov
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.